Literature DB >> 29134184

Extranodal Marginal Zone Lymphoma of Ocular Adnexa: Outcomes following Radiation Therapy.

Sean Platt1, Yahya Al Zahrani1, Nakul Singh2, Brian Hill3, Sheen Cherian4, Arun D Singh1.   

Abstract

AIM: The aim of this study was to report outcomes following radiation therapy in patients with biopsy-proven extranodal marginal zone lymphoma of the ocular adnexa and uvea.
METHODS: Records from a single institution were retrospectively reviewed from January 1997 to December 2015. The mean follow-up duration was 38 months (range 0-194). Radiation therapy was administered to 77 eyes (60 patients); 57 of the 77 eyes (74%) were treated with radiation only (range 20-36 Gy, median 15 fractions). Radiation cataract, radiation retinopathy, and optic neuropathy assessments were performed on all eyes treated with radiation.
RESULTS: 100% of the 47 patients treated with radiation therapy only had local control with an average dose of 26.5 Gy (median 25.2 [range 20-36] Gy; 150-200 cGy per fraction). Four patients lost 2 lines or more of vision after radiation. The most common complication of radiation therapy was cataract formation/progression in 19 eyes (25%). Radiation retinopathy was observed only in 1 patient (1%).
CONCLUSION: Our results confirm that radiation therapy (median 25 Gy) for extranodal marginal zone lymphoma of the ocular adnexa is associated with high local control and low risk of visually significant complications.

Entities:  

Keywords:  Adnexal tumors; Lymphoma; Radiation damage

Year:  2017        PMID: 29134184      PMCID: PMC5675111          DOI: 10.1159/000453615

Source DB:  PubMed          Journal:  Ocul Oncol Pathol        ISSN: 2296-4657


  40 in total

1.  Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group.

Authors:  Joachim Yahalom; Tim Illidge; Lena Specht; Richard T Hoppe; Ye-Xiong Li; Richard Tsang; Andrew Wirth
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-05-01       Impact factor: 7.038

2.  Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial.

Authors:  Lisa Lowry; Paul Smith; Wendi Qian; Stephen Falk; Kim Benstead; Tim Illidge; David Linch; Martin Robinson; Andrew Jack; Peter Hoskin
Journal:  Radiother Oncol       Date:  2011-06-12       Impact factor: 6.280

3.  Occurrence and prognosis of extranodal lymphomas.

Authors:  C Freeman; J W Berg; S J Cutler
Journal:  Cancer       Date:  1972-01       Impact factor: 6.860

4.  Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy.

Authors:  Jayant S Goda; Mary Gospodarowicz; Melania Pintilie; Woodrow Wells; David C Hodgson; Alexander Sun; Micheal Crump; Richard W Tsang
Journal:  Cancer       Date:  2010-08-15       Impact factor: 6.860

5.  Primary ocular adnexal mucosa-associated lymphoid tissue lymphoma (MALT): single institution experience in a large cohort of patients.

Authors:  Soley Bayraktar; Ulas D Bayraktar; Alexandra Stefanovic; Izidore S Lossos
Journal:  Br J Haematol       Date:  2010-11-18       Impact factor: 6.998

Review 6.  Management of marginal zone lymphomas.

Authors:  Catherine Thieblemont; Bertrand Coiffier
Journal:  Curr Treat Options Oncol       Date:  2006-05

7.  4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial.

Authors:  Peter J Hoskin; Amy A Kirkwood; Bilyana Popova; Paul Smith; Martin Robinson; Eve Gallop-Evans; Stewart Coltart; Timothy Illidge; Krishnaswamy Madhavan; Caroline Brammer; Patricia Diez; Andrew Jack; Isabel Syndikus
Journal:  Lancet Oncol       Date:  2014-02-24       Impact factor: 41.316

8.  Long-term follow-up results of observation or radiation for conjunctival malignant lymphoma.

Authors:  Toshihiko Matsuo; Tadashi Yoshino
Journal:  Ophthalmology       Date:  2004-06       Impact factor: 12.079

9.  Risk potentiality of frontline radiotherapy associated cataract in primary ocular adnexal mucosa-associated lymphoid tissue lymphoma.

Authors:  Won-Kyung Cho; Sung-Eun Lee; Ji-Sun Paik; Seok-Goo Cho; Suk-Woo Yang
Journal:  Korean J Ophthalmol       Date:  2013-07-05

10.  Extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue type of the ocular adnexa: retrospective single institution review of 95 patients.

Authors:  Su-Ho Lim; Minkyu Kang; Junhyuk Son
Journal:  Indian J Ophthalmol       Date:  2011 Jul-Aug       Impact factor: 1.848

View more
  4 in total

1.  Treatment-associated outcomes of patients with primary ocular adnexal MALT lymphoma after accurate diagnosis.

Authors:  Yuya Masuda; Kazuto Takeuchi; Toshio Kodama; Tomoaki Fujisaki; Yoshitaka Imaizumi; Eiichi Otsuka; Shuji Ozaki; Shinji Hasebe; Yoshihiro Yakushijin
Journal:  Int J Clin Oncol       Date:  2019-06-06       Impact factor: 3.402

2.  Clinical features and treatment outcomes of primary ocular adnexal mucosa-associated lymphoid tissue lymphoma: a single center retrospective analysis of 64 patients in China.

Authors:  Hui Yu; Yu-Xin Du; Zhen-Chang Sun; Xiao-Rui Fu; Nan Tan; Wei-Feng Gong; Ming-Zhi Zhang
Journal:  Int J Ophthalmol       Date:  2019-11-18       Impact factor: 1.779

Review 3.  The outcome of radiation therapy as a primary treatment in orbital lymphoma: a systematic review.

Authors:  Thalia Puteri Oktariana; Aisha Andriana; Rafiq Sulistyo Nugroho
Journal:  Rep Pract Oncol Radiother       Date:  2022-09-19

4.  Survival in B-cell primary ocular lymphoma 1997-2014: a population-based study.

Authors:  Deliang L Liu; Zhuojun J Zheng
Journal:  J Investig Med       Date:  2018-06-12       Impact factor: 2.895

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.